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Abstract: Data collected in the European Cystic Fibrosis Society Patient Registry (ECFSPR) database
were used to investigate whether risk factors for death in childhood and adolescents CF patients
have different impact in countries of different income. In this way, it is possible to recognize
where interventions could improve the quality of care and survival in these patients. We matched
deceased and alive patients by age, country, year of follow-up. Multivariable logistic models were
developed. In the years of this study, the ECFSPR collected information on 24,416 patients younger
than 18 years: 7830 patients were from countries with low/middle income and 16,586 from countries
with high income; among these the dead are 102 and 107 (p < 0.001), respectively. The use of oxygen,
forced expiratory volume in one second (FEV1) below 40% and BMI standard deviation score (SDS)
below −2 represent risk factors for death. However, some patients from countries with high income
remain alive even if their values of FEV1% and BMI-SDS were low, and some deceased patients from
countries with high income had high values of FEV1% (>60%). Evaluation of mortality in pediatric
age may reflect the availability of resources for CF diagnosis and treatment in some countries.
Keywords: mortality; childhood; lung disease; cystic fibrosis; registry
1. Introduction
Recent reports from Australian, U.S. and European cystic fibrosis (CF) registries [1–3] show that
adult patients represent more than 50% of the CF population, and the mean age of CF population is
slowly but steadily increasing. At the same time, 2014 data from registries report a proportion of death
in paediatric age ranging from 10% to 20% [Australia = 10.5% (two out of 19 patients); U.S. = 11.9%
(55 out of 461); EU = 17.7% (68 out of 385)].
Since pulmonary insufficiency is the main cause of death in CF, the potential risk factors for
pulmonary disease, which are to some extent preventable or treatable, could also be considered
potential risk factors for death.
Kerem et al. [4] investigated the associations between forced expiratory volume in one second
(FEV1) and clinical outcomes in the European Cystic Fibrosis Society Patient Registry (ECFSPR)
database. BMI, infection by Pseudomonas aeruginosa, pancreatic status and CF-related diabetes (CFRD)
showed a statistically significant and clinically important effect on FEV1. Recently, McColley et al. [5]
identified respiratory signs and symptoms at age 3–5 years as risk factors for childhood death.
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The paper of Mehta et al. [6] stated that mortality in childhood may be considered as a surrogate
marker for the ability of a country’s health care system to provide early care to patients with severe
chronic disease. The paper of McCormick et al. [7] highlighted the lack of studies on childhood
mortality. The aim of this study is to investigate whether the risk factors for death reported in literature
have different impact in countries of different income, so as to recognize the areas where interventions
could improve the quality of care and survival of CF patients.
2. Patients and Methods
The ECFSPR annually collects data on CF patients from national registries and individual
centres in Europe and neighbouring countries. The ECFSPR structure, the methods of collection,
and management of the data are described elsewhere [8,9]. The self-reported coverage varies between
the countries and years of follow-up [10].
We considered patients <18 years registered in the ECFSPR from 2008 to 2013 (the most recently
available year of follow-up at the time of this analysis). We selected patients who died, then we matched
(1:1) deceased and alive patients by age (range of two months, age at death for deceased patients, age
at follow-up for alive patients), country and year of follow-up. We considered these variables for the
matching to account for temporal and spatial differences in the diagnosis and treatment of disease
and data collection. The matched alive patient was randomly selected among those matching the
deceased patient.
Countries were classified into three groups based on tertiles of gross national income per capita,
obtained from World Bank tables [11]. Low and middle income countries were put together in one
group having a number of deaths under 18 years similar to that of high income countries.
The ECFSPR collects information on demographics, diagnosis, genetics, infections, therapies,
complications, lung function, growth and transplants. The definition of the variables recorded in
the ECFSPR are given in the ECFSPR webpage [12]. The slight differences between countries in the
definition of some variables do not affect the relationship between risk factors and mortality.
FEV1 values were expressed as percent of predicted (FEV1%) according to Wang et al. [13]
for male and female children older than 6 years, and Hankinson et al. [14] for males and females
aged ≥ 16 years. BMI standard deviation scores (SDS) of patients aged≥ 2 years were computed on the
basis of the Centres for Disease Control and Prevention references [15], and recoded as BMI-SDS < −2
and BMI-SDS ≥ −2. Due to the wide differences in the liver involvement in CF, patients were classified
as “Cirrhosis with or without hypertension/hypersplenism, or hypertension unknown” or “Liver
disease without cirrhosis”.
All patients gave their informed consent for inclusion before they participated to the ECFSPR.
The study was conducted in accordance with the Declaration of Helsinki, and the data request was
approved by the Scientific and Steering Committees of the ECFSPR, and anonymous patient data
were provided for analysis (approval: 19/02/2016). The use of the provided data was according to
Danish law.
Statistical Analysis
To investigate which risk factors had an effect on the probability of death, a two steps strategy
was adopted. In the first step, all factors, among those recorded in the ECFSPR, were grouped in
five classes:
(1) Diagnosis: Genotype, Age at diagnosis, Neonatal screening, Meconium ileus
(2) Microbiology: Chronic Pseudomonas aeruginosa, Chronic Staphylococcus aureus, Chronic
Burkholderia cepacia, Nontuberculous mycobacteria, Stenotrophomonas maltophilia
(3) Therapies: Inhaled hypertonic NaCl, Inhaled antibiotic, Inhaled bronchodilators, Use of oxygen,
Use of rhDNase, Use of macrolide, Use of ursodeoxycholic acid
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(4) Complications: Allergic bronchopulmonary Aspergillosis (ABPA), CFRD, Pneumothorax
requiring chest drain, Liver disease, Hemoptysis, Occurrence of malignancy
(5) Growth and lung function: BMI-SDS, FEV1%
A multivariable logistic model adjusted by gender was used in each class (model 1–5) to select the
risk factors significantly associated to mortality. In the second step the selected factors were entered
into a multivariable logistic model (model 6.1). Since BMI can be computed only for patients older
than 2 years and FEV1% for patients older than 6 years, we entered these variables as the last (model
6.2) to not narrow the age of the patients during the variable selection process. The same analysis
was performed on the two subgroups of countries, low/middle income and high income, in order to
investigate if the risk factors have different impact in different countries.
3. Results
For years 2008–2013, the ECFSPR collected information on 44,104 CF patients from 27 countries.
In these years, the total number of deaths was 1754 (3.97%). For the purposes of the study we
considered 24,625 patients (24,416 alive and 209 deceased) younger than 18 years with ascertained
status of life (patients not seen during the years of follow-up or lost to follow-up were excluded).
Out of the 209 deceased patients, only 186 deceased patients had one matching alive patient.
The most frequent cause of death was respiratory disease (57.0%), followed by unknown cause
(16.7%, this category can include rare complications: only a limited number of cause of death is collected
by the ECFSPR), transplantation (10.2%), non-CF related causes (10.2%), liver or gastro-intestinal
disease (4.3%), trauma (1.6%). 11.83% of patients died before their second birthday and 67.75% died
between 10 and 17 years. 65.59% of the deceased patients were female: both for males and females
more than 60% of the patients died between 10 and 17 years.
As expected, cases with severe disease were more frequent in deceased patients (Table 1).
Table 1. Main demographic and clinical characteristics of the 372 considered patients. The number of
patients and the percentage (in brackets) were reported unless otherwise stated.
Deceased (N = 186) Alive (N = 186)
Gender MaleFemale
64 (34.41)
122 (65.59)
109 (58.60)
77 (41.40)
Diagnosis
Genotype
F508del homozygote
F508del heterozygote
No F508del
Unknown
87 (46.77)
66 (35.48)
25 (13.44)
8 (4.30)
83 (44.62)
73 (39.25)
25 (13.44)
5 (2.69)
Age at diagnosis (years), median (N) 0.30 (175) 0.31 (174)
Age at diagnosis
<1 year
1–17 years
Unknown
132 (70.97)
43 (23.12)
11 (5.91)
114 (61.29)
60 (32.26)
12 (6.45)
Neonatal screening
Not performed
Performed
Unknown
87 (46.77)
36 (19.35)
63 (33.87)
79 (42.47)
53 (28.49)
54 (29.03)
Meconium ileus
No
Yes
Unknown
130 (69.89)
37 (19.89)
19 (10.22)
145 (77.96)
23 (12.37)
18 (9.68)
Transplant
Liver transplant
No
Yes
Unknown
178 (95.70)
1 (0.54)
7 (3.76)
180 (96.77)
0 (0.00)
6 (3.23)
Lung transplant
No
Yes
Unknown
152 (81.72)
30 (16.13)
4 (2.15)
182 (97.85)
0 (0.00)
4 (2.15)
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Table 1. Cont.
Deceased (N = 186) Alive (N = 186)
Microbiology
Chronic Pseudomonas aeruginosa
No
Yes
Unknown
73 (39.25)
77 (41.40)
36 (19.35)
132 (70.97)
38 (20.43)
16 (8.60)
Chronic Staphylococcus aureus
No
Yes
Unknown
66 (35.48)
31 (16.67)
89 (47.85)
71 (38.17)
45 (24.19)
70 (37.63)
Chronic Burkholderia cepacia
No
Yes
Unknown
142 (76.34)
12 (6.45)
32 (17.20)
167 (89.78)
2 (1.08)
17 (9.14)
Nontuberculous mycobacteria
No
Yes
Unknown
139 (74.73)
4 (2.15)
43 (23.12)
151 (81.18)
3 (1.61)
32 (17.20)
Stenotrophomonas maltophilia
No
Yes
Unknown
141 (75.81)
9 (4.84)
36 (19.35)
146 (78.49)
18 (9.68)
22 (11.83)
Therapy
Inhaled hypertonic NaCl
No
Yes
Unknown
115 (61.83)
37 (19.89)
34 (18.28)
129 (69.35)
42 (22.58)
15 (8.06)
Inhaled antibiotic
No
Yes
Unknown
72 (38.71)
82 (44.09)
32 (17.20)
118 (63.44)
59 (31.72)
9 (4.84)
Inhaled bronchodilators
No
Yes
Unknown
56 (30.11)
95 (51.08)
35 (18.82)
78 (41.94)
93 (50.00)
15 (8.06)
Use of oxygen
No
Yes
Unknown
70 (37.63)
83 (44.62)
33 (17.74)
169 (90.86)
4 (2.15)
13 (6.99)
Use of rhDNase
No
Yes
Unknown
58 (31.18)
103 (55.38)
25 (13.44)
74 (39.78)
107 (57.53)
5 (2.69)
Use of macrolide
No
Yes
Unknown
75 (40.32)
74 (39.78)
37 (19.89)
120 (64.52)
51 (27.42)
15 (8.06)
Use of ursodeoxycholic acid
No
Yes
Unknown
68 (36.56)
87 (46.77)
31 (16.67)
99 (53.23)
82 (44.09)
5 (2.69)
Use of pancreatic enzymes
No
Yes
Unknown
13 (6.99)
146 (78.49)
27 (14.52)
22 (11.83)
160 (86.02)
4 (2.15)
Complication
ABPA
No
Yes
Unknown
137 (73.66)
25 (13.44)
24 (12.90)
160 (86.02)
16 (8.60)
10 (5.38)
CFRD
No
Yes
Unknown
120 (64.52)
45 (24.19)
21 (11.29)
168 (90.32)
13 (6.99)
5 (2.69)
Pneumothorax requiring chest drain
No
Yes
Unknown
154 (82.80)
11 (5.91)
21 (11.29)
179 (96.24)
1 (0.54)
6 (3.23)
Liver disease
No
Yes
Unknown
95 (51.08)
64 (34.41)
27 (14.52)
145 (77.96)
25 (13.44)
16 (8.60)
Haemoptysis
No
Yes
Unknown
145 (77.96)
17 (9.14)
24 (12.90)
176 (94.62)
1 (0.54)
9 (4.84)
Occurrence of malignancy
No
Yes
Unknown
158 (84.95)
1 (0.54)
27 (14.52)
173 (93.01)
0 (0.00)
13 (6.99)
Growth and
lung function
BMI-SDS (only patients
2 years old or more)
<−2
≥−2
Unknown
45 (27.44)
49 (29.88)
70 (42.68)
10 (6.13)
145 (88.96)
8 (4.91)
FEV1% *
<40
≥40
Unknown
28 (23.33)
22 (18.33)
70 (58.33)
6 (4.03)
128 (85.91)
15 (10.07)
* excluding patients under 6 years of age and those who received a lung transplant.
Gender, age at diagnosis, neonatal screening, chronic Pseudomonas aeruginosa, chronic
Staphylococcus aureus, oxygen supplementation, CFRD, pneumothorax requiring chest drain,
liver disease, haemoptysis, BMI and FEV1 resulted significantly associated to mortality (Figure 1).
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Figure 1. Results of the first step strategy: they are expr as OR and 95% confide c interval
(CI). All factors, among those r corde in the ECFSPR, were groupe i fiv cl : iagnosis (1),
microbiology (2), therapies (3), complications (4), growth and lung function (5), Chr: chronic.
All these variables were considered in the second step of the analysis, except haemoptysis and
pneumothorax requiring chest drain (only 1 alive patient with one of these conditions). Among
these variables (except BMI-SDS and FEV1%, available only for patients over 2 and 6 years,
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respectively), when simultaneously included into a logistic model (model 6.1), only gender and
oxygen supplementation resulted significantly associated to mortality. BMI-SDS and FEV1%, added to
the model (model 6.2), appeared significantly associated to mortality, with a reduced effect of gender
and use of oxygen (Table 2).
Table 2. Effect of selected factors on mortality in the set of patients under 18, and in the subset of
patients 6 to 18 years old.
OR 95% CI
Model 6.1: 136 observations used
Gender: F vs. M 5.626 1.878 16.853
Neonatal screening: Not performed vs. Performed 0.755 0.235 2.421
Use of oxygen: Yes vs. No 48.608 8.173 289.070
CFRD: Yes vs. No 3.646 0.832 15.991
Liver disease: Yes vs. No 1.935 0.673 5.568
Chronic Pseudomonas aeruginosa: Yes vs. No 2.512 0.852 7.410
Chronic Staphylococcus aureus: Yes vs. No 0.483 0.172 1.353
Age at diagnosis 0.835 0.604 1.153
Model 6.2: 172 observations used
Gender: F vs. M 4.118 1.211 14.005
Use of oxygen: Yes vs. No 20.787 4.336 99.668
BMI-SDS (patients aged 2 or more): <−2 vs. ≥−2 7.975 2.403 26.461
FEV1% *, <40 vs. ≥40 6.999 1.997 24.524
* excluding patients under 6 years of age and those who received a lung transplant.
The interaction between BMI and FEV1 was not significant. In the years of this study, the
ECFSPR collected information on 12,867 patients from 17 countries with low/middle income and
31,237 patients from 10 countries with high income. Seven thousand eight hundred thirty patients
younger than 18 years were from countries with low/middle income and among these 102 died (1.30%);
16,586 patients younger than 18 years were from countries with high income and among these 107 died
(0.64%). The difference was statistically significant (p < 0.001).
Lithuania reported no data on children or adolescent patients and for Latvia and Republic of
Moldova deceased patients did not have a living matching patient. 5 countries do not report deceased
patients. Therefore, the 372 patients included in the analysis were from 19 countries (Table 3).
Table 3. ECFSPR countries by group of income.
Number of Ptients
Income Countries total total < 18 years deaths < 18 years
Low/middle
Hungary, Lithuania, Republic of Macedonia *, Republic of
Moldova, Romania *, Russian Federation, Serbia, Ukraine, Czech
Republic, Greece, Israel, Italy, Latvia, Portugal, Slovakia *,
Slovenia * and Spain
12,867 7830 102
High Austria, Belgium, Denmark, France, Germany, Ireland, TheNetherlands, Sweden, Switzerland * and United Kingdom 31,237 16,586 107
* no deceased patients from this country.
To investigate if the risk factors for death differed across European countries, we performed the
same analysis considering the two subgroups of countries, high income and low/middle income.
Since the number of patients considered for these models is small, the 95% CI is too large, therefore
we decided to report only the low limit of it: in this way we report an estimate of the minimum risk.
For the group of countries with high income, use of oxygen, FEV1% and BMI-SDS were associated
with the probability of death. The odds of dying was 4.7 (low limit of the 95% CI of the OR) times
higher in patients that use oxygen, the odds of dying was 1.2 times higher in patients with FEV1%
below 40%; patients with a BMI-SDS below −2 had an odds of dying 2.9 times higher than that of
patients with a BMI-SDS above −2 SDS.
For the group of countries with low/middle income, oxygen supplementation was not significant
and no longer considered into the final model. The odds of dying was 6.7 (low limit of the 95% CI of
the OR) times higher in patients with FEV1% below 40% than in patients with FEV1% above or equal
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to 40%. Patients with a BMI-SDS below −2 had an odds of dying that was 1.3 (low limit of the 95% CI)
times higher than patients with a BMI-SDS above −2 SDS.
Figure 2 shows the distribution of living (2a) and deceased (2b) patients by lung function and
nutrition in low/middle and high income countries. Some patients from countries with high income
remain alive even if their values of FEV1% and BMI-SDS were low (<60% and <0, respectively).
Some deceased patients from countries with high income had high values of FEV1% (>60%).
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4. Discussion
Our study investigated risk factors for death in patients younger than 18 years using ECFSPR
data. The childhood mortality may be considered as a surrogate marker for the ability of a country’s
health care system [6]. For this reason, we investigated whether the risk factors for death have different
impact in countries of different income for recognizing where interventions could improve the quality
of care and survival of CF patients.
In the ECFSPR, the percentage of death in paediatric age (11.9%) is similar to those reported in
the Australian registry [1] and in the CF Foundation (CFF) Patient Registry [2]. McColley et al. [5]
using clinical data from the Epidemiologic Study of CF [16] showed that also digital clubbing or chest
crackles between 3 and 5 years of age, both signs of early severe pulmonary involvement, associated
with worse lung disease, are risk factors for death.
According to literature, among the risk factors for early death considered in the first step of our
analysis, those resulted significantly associated with higher probability of death are: female gender,
high age at diagnosis, unavailability of newborn screening (NBS), chronic infection by Pseudomonas
aeruginosa or by Staphylococcus aureus, use of oxygen, CFRD, pneumothorax requiring chest drainage,
liver disease, haemoptysis, BMI-SDS below−2 and FEV1% below 40%. As expected, except for gender,
age at diagnosis and NBS, the major risk factors identified in this study, as well as in literature,
are CF complications.
An OR significantly below 1 for the age at diagnosis and significantly above 1 for the unavailability
of NBS means that in the absence of a CF NBS program, the early appearance of symptoms should be
considered a negative prognostic factor, and probably patients diagnosed later have a milder disease.
The diagnosis due to a positive NBS seems to be a protective factor from early death [17] even for
severe CF.
When the variables found to be significantly associated with mortality in the first step of our
analysis were simultaneously included in a multivariable model, respiratory failure (need for oxygen
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and FEV1% < 40%) and malnutrition (BMI-SDS < −2) emerged as significantly associated with death.
Gender appeared associated with mortality: we observe an OR of 4.118, suggesting that female gender
could be a risk factor. The reason for the gender gap in CF is still not clear [18] although several
hypotheses have been formulated [19–22].
Chronic Pseudomonas aeruginosa and Staphylococcus aureus respiratory infections, presence of
diabetes or liver disease are no longer significant: indeed, all these CF features are reported to
negatively influence both nutritional status and respiratory function [23]. However, recommendations
for early detection and treatment of the severe form of lung disease in children, together with timing
for referring to lung transplant, are still lacking [24,25].
It is noticeable that the prevalence of CFRD among CF deceased patients was higher than among
CF living patients (24.2% vs. 7%). Conversely, as prevalence of CFRD is less than 5% in the whole CF
paediatric population reported in the ECFSPR, a wider dissemination of paediatric diabetes screening
and therapy guidelines in CF subjects is desirable, in order to achieve early treatment [26].
We can consider that risk factors not included in the final model have effect on the worsening of
both the pulmonary function (need for oxygen and FEV1% < 40%) and the nutritional status, therefore
these two factors are sufficient to identify patients at risk.
Kerem et al. [4] showed BMI has the greatest impact on lung disease. Patients with poor BMI
experienced a six-fold increased odds of severe lung disease. Our results confirmed that almost (87%)
all the deceased patients younger than 18 years had a BMI-SDS less than 0; so the importance of good
nutritional status in childhood should be emphasized.
Guidelines concerning diagnosis and treatment in NBS positive CF infants [27], and guidelines
about the management of nutritional problems, diagnosis and treatment of diabetes in the paediatric
age [28,29] are available. A paper [30] gives evidence-based consensus recommendations for the care
of CF preschool children on routine surveillance for pulmonary disease, therapeutics and nutritional
and gastrointestinal care. Moreover, a good nutritional status in early childhood is associated with
improved survival [31].
The same analysis, performed by country grouping, came at the same conclusions as the analysis
considering all the countries together: only the use of oxygen, FEV1% < 40% and BMI-SDS < −2 were
found to be significantly associated with death. However, the percentage of deceased patients younger
than 18 years (over the total population < 18 years), is higher for countries with low/middle income
(1.3%) than for high income countries (0.64%). Evaluation of mortality in paediatric age may reflect the
availability of resources for CF diagnosis and treatment. However to check this hypothesis further ad
hoc studies are needed. Furthermore, we observed that some deceased patients from countries with
high income had higher values of FEV1% and of BMI. On the contrary, some patients were still alive
even if their values of FEV1% and BMI were very low. It should be noted that the FEV1% value does
not always reflect the severity of the lung disease, as shown by studies on thoracic imaging using CT
scan [32]. Our results can also be explained by the complexity of both CF disease and its management.
As discussed by Oates et al. [33] several non-genetic factors including health care can influence CF
disease progression and outcomes.
The study has some limitations: Macedonia, Moldova and Romania (low income), and Latvia,
Slovakia and Slovenia (middle income) do not report patients who died in childhood/adolescenthood.
Furthermore, as regards Lithuania (low income), ECFSPR does not have any information on CF patients
in the paediatric age. ECFSPR data might not properly describe the mortality of CF populations
younger than 18 years for countries with low/middle income: these can be countries where CF
diagnosis is difficult and where patients can die before receiving the correct diagnosis.
5. Conclusions
Based on our results we might no more define CF as a lethal disease in childhood, at least
in patients followed by specialized care centres. Our results highlight the need for quality of care
improvements: health policies interventions that promote early diagnosis of CF patients through NBS
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programmes [34,35] should be encouraged and the performance of existing NBS programmes carefully
monitored [36]. Early diagnosis can preserve lungs from damage in childhood, contributes to a better
nutritional status with improved growth [31] and reduces the burden of care for families and may
improve survival [17].
The identification of paediatric patients at risk of death through FEV1 < 40% and use of oxygen
might be too tardive in order to perform useful treatment actions to change the prognosis. Therefore,
CF centres should implement diagnostic tools to identify patients at risk earlier, using lung CT scan and
bronchoalveolar lavage; lung clearance index [37] to identify those patients who need more intensive
nutritional and respiratory care. As a consequence, guidelines for the diagnosis and treatment of
patients with early onset of severe respiratory disease, aggressive nutritional support for CF patients
and improvement in early diagnosis of CFRD are desirable in the paediatric settings.
Due to the importance of this topic, these results should be shared and deeply discussed with
health care authorities in each country in order to orient health policies in terms of prevention.
The results obtained have some limitations: it will be interesting to perform a new analysis on ECFSPR
mortality data in paediatric age. An ad hoc study can help to identify those countries that can benefit
from interventions to improve the quality of care and survival of CF patients.
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